DelfaGLP-1 Atlas

Lead sponsor

PegBio Co., Ltd.

7 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

7

Trials led

0

Active

1,141

Total enrollment

6

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
4
Phase 1/2
1
Phase 3
2

Trials by status

Completed
6
Unknown
1

Trials led

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin MonotherapyBMI ≤40Ph 3Completed620
PB119BMI ≤40Ph 3Completed273
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating StudyBMI 20-30Ph 1Completed82
Clinical Trial for PB-119 in Healthy Subjects (Phase I)BMI 19-24Ph 1Completed70
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.BMI ≥28Ph 1/2Completed36
Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus—Ph 1Completed36
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal FunctionBMI 18-30Ph 1Unknown24